Saturday, 1 April 2017

Report Analysis and Forecast on Colorectal cancer 2023

Colorectal cancer - Market Insights, Epidemiology and Market Forecast-2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease and global market size of the Colorectal Cancer (CRC) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed cases of Colorectal Cancer (CRC) from 2013-2023. According to DelveInsight, the 7MM Diagnosed cases for Colorectal Cancer are expected to increase, with total 514,148 cases in 2023.
According to this report, the 7 MM market size of Colorectal Cancer market is estimated to be USD 11682 million by 2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Key Coverage and Benefits:• The report will help in developing business strategies by understanding the trends shaping and driving the global Colorectal Cancer market.
• Organize sales and marketing efforts by identifying the best opportunities for Colorectal Cancer in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan. 
• To understand the future market competition in the global Colorectal Cancer market and Insightful review of the key market drivers and barriers.
• The Report also covers the detailed global historical and forecasted Colorectal Cancer market covering United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.
Scope• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options. 
• Marketed information including available prescription drugs, its patent and exclusivity details.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides market size of Colorectal Cancer for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Detailed Study of the Chemotherapy Induced Nausea and Vomiting (CINV) 2023

Chemotherapy Induced Nausea and Vomiting (CINV) - Epidemiology Insights - 2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease, historical and forecasted epidemiological data for the Incident cases of Chemotherapy Induced Nausea and Vomiting (CINV) from 2013-2023 for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. 
Chemotherapy-induced nausea and vomiting (CINV) are both severe side effects of cancer treatment. CINV is a condition which makes a patient uncomfortable and has to be dealt properly as many patients delay their chemotherapy cycles or even refuse further treatment due to fear from future nausea and vomiting. Also, due to nausea and vomiting induced by chemotherapy, patients can’t get nutrition properly and lose their energy and may become weak which may hinder the further chemotherapy cycles as patient wouldn’t be physically string to bear the chemotherapy side-effects.
According to this report, the Incident cases Chemotherapy Induced Nausea and Vomiting (CINV) is increasing and is expected to be 2, 79,634 by 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Chemotherapy Induced Nausea and Vomiting (CINV) market.
Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.
The Report covers the detailed historical and forecasted Chemotherapy Induced Nausea and Vomiting (CINV) epidemiology cases covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Growth Prospects of the Acromegaly and Gigantism To 2023

Acromegaly and Gigantism- Epidemiology Forecast To 2023 is a new market research publication announced by Reportstack. This report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis.
Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults occurs mainly in middle-aged men and women. In This condition, the bones increase in size, including those of the hands, feet and face. Acromegaly is uncommon and physical changes occur gradually thus the condition often isn't recognized immediately and if not treated promptly, it can lead to serious illness and even become life-threatening. According to the estimates, the prevalent cases of Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
Gigantism is excessive production of GH in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood. According to the estimates, prevalent cases of Gigantism in the 6 MM are expected to increase with a CAGR of 2% and Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Acromegaly and Gigantism. 
Identifying prevalent patient populations as well as risk factors in the global Acromegaly and Gigantism market will help to improve product design, pricing, and launch plans.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Market Research on Acromegaly and Gigantism To 2023

Acromegaly and Gigantism- Epidemiology Forecast To 2023 is a new market research publication announced by Reportstack. This report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk factors, disease burden with special emphasis.
Acromegaly is a rare but serious hormonal disorder caused by excessive growth hormone (GH) in the blood in adults. Acromegaly in adults occurs mainly in middle-aged men and women. In This condition, the bones increase in size, including those of the hands, feet and face. Acromegaly is uncommon and physical changes occur gradually thus the condition often isn't recognized immediately and if not treated promptly, it can lead to serious illness and even become life-threatening. According to the estimates, the prevalent cases of Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023.
Gigantism is excessive production of GH in children which is extremely rare and leads to exaggerated bone growth and an abnormal increase in height. It results from high linear growth due to excessive action of insulin like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood. According to the estimates, prevalent cases of Gigantism in the 6 MM are expected to increase with a CAGR of 2% and Acromegaly in the 7 MM are expected to increase with a CAGR of 0.72% for the forecast period i.e., 2013-2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Acromegaly and Gigantism. 
Identifying prevalent patient populations as well as risk factors in the global Acromegaly and Gigantism market will help to improve product design, pricing, and launch plans.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Research delivers insight into the Interstitial Cystitis 2023

Interstitial Cystitis - Epidemiology Insights -2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease. The Report includes global forecast of epidemiology of Interstitial Cystitis till 2023. Interstitial cystitis (IC) also known as painful bladder syndrome is a chronic disease that results in recurring discomfort or pain in the bladder and the surrounding pelvic region. This is considered as multiple bladder condition as it can lead to many other problems. Current studies estimate that 2.7% to 6.5% of women in the United States have symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS). PBS/IC is more common in women, with a female/male ratio that ranges from 5:1 to 10:1 and the Median age at diagnosis is 42 to 46 yr old whereas men are diagnosed at a younger age. 
According to this report, the number of Incident Probable IC cases in 7 major markets is expected to reach 1,97,086 cases in 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
The report will help in developing business strategies by understanding the trends shaping and driving the global Interstitial Cystitis scenario. 
Review of the key market drivers and barriers. 
To understand the regulatory scenario in major markets. 
The Report covers the detailed global historical and forecasted Interstitial Cystitis Epidemiology covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Report sheds light on the Urinary Incontinence 2023

Urinary Incontinence - Epidemiology Forecast To 2023 is a new market research publication announced by Reportstack. This report provides an overview of the disease and epidemiology trends of the Urinary Incontinence for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Urinary Incontinence from 2013-2023. 
Urinary Incontinence is a multifactorial syndrome which occurs due to the failure of the storage function of the lower urinary tract and loss of bladder control resulting in leakage of urine. Embarrassment, isolation, and depression are observed among patients with Urinary Incontinence. Millions of individuals worldwide are suffering from Urinary Incontinence. It is most common among the old people. It increases the chances of developing several medical conditions such as local skin irritation, rashes, and urinary infections.
According to this report, the prevalent cases of Urinary Incontinence are estimated to be 97,122,858 by 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
Report covers the disease overview including pathophysiology, symptoms, diagnosis, and disease management. 
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Recent Research into the Sarcopenia - Epidemiology Forecast To 2023

Sarcopenia - Epidemiology Forecast To 2023 is a new market research publication announced by Reportstack. This report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition. 

Complete report available @ ​Sarcopenia - Epidemiology Forecast To 2023
According to this report, the prevalent cases of Sarcopenia in 7 MM are expected to increase and reach up to 42,969,489 cases by the end of year 2023. 
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the global epidemiology of Sarcopenia. 
Identifying prevalent patient populations as well as risk factors of Sarcopenia.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:
Subscribe to: Posts (Atom)